Rhythm Pharmaceuticals, Inc.

NasdaqGM:RYTM Voorraadrapport

Marktkapitalisatie: US$3.2b

Rhythm Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO Rhythm Pharmaceuticals is David Meeker, benoemd in Jul2020, heeft een ambtstermijn van 4.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.23M, bestaande uit 9.7% salaris en 90.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.29% van de aandelen van het bedrijf, ter waarde $ 9.25M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 5.4 jaar.

Belangrijke informatie

David Meeker

Algemeen directeur

US$7.2m

Totale compensatie

Percentage CEO-salaris9.7%
Dienstverband CEO4.3yrs
Eigendom CEO0.3%
Management gemiddelde ambtstermijn4yrs
Gemiddelde ambtstermijn bestuur5.4yrs

Recente managementupdates

Recent updates

Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Sep 23
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly?

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Sep 22

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 29

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Jun 12

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 09
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

May 05
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares May Have Run Too Fast Too Soon

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Mar 03
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$57.22

Rhythm Pharmaceuticals: Action Too Specific

Feb 23

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Jan 08
Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

Nov 03
We're Hopeful That Rhythm Pharmaceuticals (NASDAQ:RYTM) Will Use Its Cash Wisely

We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Jul 23
We're Not Very Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Rate

Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Jun 17
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Popularity With Investors Is Under Threat From Overpricing

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

May 05
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Cutting Their Estimates

Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

Apr 01
Rhythm Pharmaceuticals (NASDAQ:RYTM) Is In A Good Position To Deliver On Growth Plans

An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

Dec 15
An Intrinsic Calculation For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Suggests It's 46% Undervalued

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Oct 24
We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully

Rhythm Pharmaceuticals: Revisiting The Investment Thesis

Oct 10

Rhythm Pharmaceuticals announces $100M stock offering; shares fall 12% after hours

Sep 14

Rhythm Pharma's Imcivree drug gets expanded approval by European Commission for BBS

Sep 06

Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Aug 08
Industry Analysts Just Made An Incredible Upgrade To Their Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Revenue Forecasts

Rhythm Pharmaceuticals Q2 2022 Earnings Preview

Aug 01

Rhythm Pharma gains as NICE recommends obesity drug

Jul 18

Analyse CEO-vergoeding

Hoe is David Meeker's beloning veranderd ten opzichte van Rhythm Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$261m

Mar 31 2024n/an/a

-US$274m

Dec 31 2023US$7mUS$705k

-US$185m

Sep 30 2023n/an/a

-US$186m

Jun 30 2023n/an/a

-US$182m

Mar 31 2023n/an/a

-US$181m

Dec 31 2022US$3mUS$652k

-US$181m

Sep 30 2022n/an/a

-US$181m

Jun 30 2022n/an/a

-US$176m

Mar 31 2022n/an/a

-US$166m

Dec 31 2021US$6mUS$630k

-US$70m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$15mUS$262k

-US$134m

Sep 30 2020n/an/a

-US$132m

Jun 30 2020n/an/a

-US$134m

Mar 31 2020n/an/a

-US$146m

Dec 31 2019US$287kn/a

-US$141m

Sep 30 2019n/an/a

-US$133m

Jun 30 2019n/an/a

-US$115m

Mar 31 2019n/an/a

-US$87m

Dec 31 2018US$282kn/a

-US$74m

Sep 30 2018n/an/a

-US$59m

Jun 30 2018n/an/a

-US$53m

Mar 31 2018n/an/a

-US$47m

Dec 31 2017US$268kn/a

-US$38m

Compensatie versus markt: De totale vergoeding ($USD 7.23M ) David } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.66M ).

Compensatie versus inkomsten: De vergoeding van David is gestegen terwijl het bedrijf verliesgevend is.

CEO

David Meeker (70 yo)

4.3yrs

Tenure

US$7,230,457

Compensatie

Dr. David P. Meeker, M.D., had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 2021 and serves as its Independent Non-Executive Chair. Dr. Meek...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
David Meeker
Chairman4.3yrsUS$7.23m0.29%
$ 9.3m
Hunter Smith
CFO & Treasurer7.3yrsUS$2.31m0.16%
$ 5.2m
Joseph Shulman
Chief Technical Officer4.3yrsUS$1.74m0.000050%
$ 1.6k
Yann Mazabraud
Executive VP & Head of International4.1yrsUS$1.74m0.057%
$ 1.8m
Jennifer Lee
Executive VP & Head of North America4yrsUS$2.11m0.011%
$ 363.1k
Christopher German
Corporate Controller1.7yrsgeen gegevens0.0013%
$ 42.1k
Alastair Garfield
Chief Scientific Officerless than a yeargeen gegevensgeen gegevens
David Connolly
Head of Investor Relations & Corporate Communicationsno datageen gegevensgeen gegevens
Jim Flaherty
Senior VP & General Counsel4yrsgeen gegevensgeen gegevens
Sarah Ryan
Vice President of Sales & Marketingno datageen gegevensgeen gegevens
Pamela Cramer
Chief Human Resources Officer3.3yrsgeen gegevens0.022%
$ 715.3k
Elisabeth Cronert-Bendell
Senior VP & Head of Strategy2.8yrsgeen gegevensgeen gegevens

4.0yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RYTM wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
David Meeker
Chairman9yrsUS$7.23m0.29%
$ 9.3m
Christopher German
Corporate Controller1.7yrsgeen gegevens0.0013%
$ 42.1k
Jennifer Good
Independent Director5.4yrsUS$283.77k0.0049%
$ 159.1k
David W. McGirr
Independent Director9yrsUS$308.77k0.0049%
$ 159.1k
Edward Mathers
Lead Independent Director11.7yrsUS$328.77k0.014%
$ 464.9k
Lynn Tetrault
Independent Director3.9yrsUS$298.77k0.0049%
$ 159.1k
William Chin
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Elizabeth Stoner
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Michael Camilleri
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Lee Kaplan
Chairman of Scientific Advisory Boardno datageen gegevensgeen gegevens
John Amatruda
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Stuart Arbuckle
Independent Director5.3yrsUS$301.27k0.0049%
$ 159.1k

5.4yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RYTM wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).